ASP Isotopes' Helium Plant Begins Commissioning, but Isotope Revenue Still at Zero

What happened

ASP Isotopes announced that Tetra4, a subsidiary of Renergen (which ASPI acquired), has commenced commissioning of the Phase 1 liquid helium plant in South Africa after engineering optimization. The company expects to deliver liquid helium to customers in September 2026 and ramp production to nameplate capacity during the second half, in a market facing acute global shortage. Following a successful Phase 1 start-up, ASPI plans to advance Phase 2 during 2H 2026 and is exploring ways to accelerate revenues and cash flows from that phase. However, this progress is confined to the helium/LNG segment and does not address the central investor concern: ASPI still has not reported any revenue from the sale of enriched isotopes as of March 31, 2026. The helium milestone was already anticipated in the company roadmap, and while it may improve near-term cash flow, the larger Phase 2 project carries a $1.16 billion cost with only conditional financing, so equity dilution risk remains.

Implication

Investors should treat this news as incremental progress on the helium/LNG track, consistent with prior guidance that Phase 1 would reach nameplate by Q3 2026. Successful commissioning and September helium deliveries could provide early evidence of operational execution and possibly positive operating cash flow by year-end, but that alone is insufficient to re-rate the equity. The core thesis still hinges on recognized isotope product revenue, which has been zero through Q1 2026 despite plants in commercial production. The announcement does not change the conditional nature of Phase 2 financing or the risk of substantial additional capital needs, which could lead to dilution. Maintain the WAIT rating and attractive entry of $4.75; only a confirmed quarter with isotope sales revenue or TerraPower drawdowns would prompt an upgrade.

Thesis delta

No material thesis shift. The commissioning milestone was already embedded in the roadmap and does not alter the judgment that ASPI remains a WAIT until it converts production into recognized isotope revenue. The helium segment remains a secondary cash-flow bridge, but the larger value driver and risk remain isotope commercialization and Phase 2 capital discipline.